Of note, our data showed that MEK inhibition-based triplets were able to kill CR-CSCs in the presence of cytokines released by CAFs and to induce tumour regression in all CR-CSC-based xenografts tested, regardless of the mutational status and Erbb2 amplification. This evidence concerns the gene ERBB2 and neoplasm.